Some tech stories make me roll my eyes at the hype. This isn't one of them. The FDA has approved a breakthrough cancer medication more than six months ahead of schedule after trial results that researchers are calling, in their own words, unprecedented. The treatment nearly doubled median survival in trials, and that's the kind of number that makes even grizzled oncologists sit up straight. You can read the full report over at Yahoo News.

Let me explain why the timing matters as much as the results. Drug approvals usually move at a glacial pace, and for good reason, safety takes time. When the FDA clears something six months early, it means the data was so strong that waiting felt almost irresponsible. I remember when a fast-tracked approval meant shaving off a few weeks of paperwork. Six months is a different animal entirely.

The headline figure is median survival nearly doubling. For the families sitting in oncology waiting rooms right now, that number isn't abstract. It's birthdays, it's graduations and, if I may be a grandmother for a moment, more time to spoil the grandkids. My granddaughter Jess will tell you I'm a sucker for extra time with family, and I make no apologies for it.

I cover gadgets most days, phones and smart locks and robot vacuums, but science like this is why I fell in love with this beat in the first place. Technology should work for you, and there's no clearer example of that than a treatment that gives people back years of their lives. The molecular work happening underneath these trials is astonishing. My colleague Marcus could explain the mechanism in glorious detail, and the immunotherapy research he's covered over the years laid the groundwork for moments exactly like this one.

Now, a bit of patience from me, because I'd be doing you a disservice otherwise. "Nearly doubled median survival" is a median, which means individual results vary. Some patients will see far less benefit, some potentially more. And approval is the beginning of a long road, not the finish line: access, insurance coverage, and figuring out which patients respond best all take time. If you or someone you love is dealing with cancer, take this news as hope, but don't change treatment plans without a long talk with your oncologist.

Still. I've watched four decades of technology change lives, from the Macintosh on a stage in 1984 to phones that outperform the supercomputers of my youth. Nothing in all those years matches the feeling of watching medicine pull off something doctors themselves call unprecedented...

I'll keep an eye on how this rolls out and who can actually get it, because a breakthrough only matters if it reaches the people waiting for it.